The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the promise for blockbuster treatments and significant returns is certain, the associated risks are also considerable.